Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

First form of therapy for childhood dementia CLN2 developed

25.04.2018

In an international study, scientists of the University Medical Center Hamburg-Eppendorf (UKE) have discovered a new therapeutic approach for Late Infantile Neu-ronal Ceroid Lipofuscinosis (CLN2) – a form of childhood dementia. Enzyme replace-ment therapy with cerliponase alfa can have beneficial effects.

It was possible to stop the illness from progressing for two thirds of the patients. The synthetic enzyme is introduced into the subarachnoid space of the patient via a cathe-ter every 14 days. The scientists have now published their findings in the New England Journal of Medicine.


Dr. Angela Schulz, the director of the international study

Universitätsklinikum Hamburg-Eppendorf

"So far, the only treatment available to CLN2 patients has been palliative care. This situation has been fundamentally changed by the approval of an enzyme replacement therapy, which was researched by UKE doctors. The study has shown that this is the first form of therapy that can counter the rapid progress of the illness", said Professor Dr. Ania C. Muntau, Director of the Children's Clinic.

"The earlier CLN2 is diagnosed and treatment is started, the higher the chances are for the therapy to be successful, enabling the children who have acquired the illness to be able to maintain speech for longer and to move independently. But this illness is often discovered too late because it is very rare.

Therefore, I would wish that it would soon be possible in Germany to test all children for CLN2 as part of a screening procedure for newly born", said Dr. Angela Schulz, the director of the internation-al study and the consultation hour for degenerative brain diseases (focus "Childhood Dementia NCL") at the Children's Clinic at UKE.

Neuronal ceroid lipofuscinosis (CLN2)

Neuronal ceroid lipofuscinosis (NCL) is a rare illness. The most frequent form is subtype CLN2, where the enzyme tripeptidyl peptidase I (TPP1) is not, or not sufficiently, formed. Thus, the pigment cerois lipofuscin accumulates in the brain cells, which initially lose their function, and ultimately die.

Usually, children with CLN2 develop normally up to the age of three. The only indication can be the delayed development of the children's speech. The first symptoms only become apparent between the second and fourth year. The children have severe epileptic seizures, and language and motor skills regress. In their fifth year, children can no longer sit or stand, and require a wheelchair. They become bedridden, blind, and usually die early.

The international multi-centric study

24 CLN2 patients between the age of three and eight received enzyme replacement therapy with cerliponase alfa every 14 days for at least 96 weeks as part of the international, multi-centric study. The scientists in the study centres in Hamburg, London, Rome and Columbus (USA) documented the development of motor skills and language with a point based system, and compared the course of the disease with 42 historical patients who had not been treated with enzyme replacement.

The his-torical comparative data had previously been collected and evaluated as part of the European Framework Programme (FP7) DEM-CHILD coordinated at UKE by Dr. Schulz. The comparison with untreated children showed that the symptoms of patients who received enzyme replacement thera-py worsened significantly more slowly than those of the historical group of patients: on average, treated patients only lost 0.38, but untreated patients lost 2.0 points per year.

Research of rare illnesses at Children's UKE

Children's UKE, the Werner and Michael Otto University Children's Clinic (Werner und Michael Otto Universitätskinderklinik, Kinder-UKE), treats the most important pediatric illnesses. The particular focus is on severe, rare, complex, and undetermined illnesses such as metabolic disorders, neurologi-cal illnesses, various types of cancer, and liver, kidney, and bone marrow transplants.

Furthermore, the development of innovative treatment methods for children with rare illnesses belongs to the core tasks of the Children's UKE. Thus, the scientists conduct basic research to improve understanding of the mechanisms which cause the illness. They also develop medication and lead international ap-proval studies.

Literature
Schulz A. et al., Study of Intraventricular Cerliponase Alfa for CLN2 Disease, New England Journal of Medicine 2018
DOI: https://doi.org/10.1056/NEJMoa1712649

Please follow this link for photographs on the subject of NCL: www.uke.de/pressebilder

Contact
Dr. Angela Schulz
Klinik und Poliklinik für Kinder- und Jugendmedizin
Universitätsklinikum Hamburg-Eppendorf (UKE)
Martinistraße 52
20246 Hamburg
Telephone: 040 7410-20440
an.schulz@uke.de

Saskia Lemm | idw - Informationsdienst Wissenschaft
Further information:
http://www.uke.de

More articles from Studies and Analyses:

nachricht Innovative genetic tests for children with developmental disorders and epilepsy
11.07.2018 | Christian-Albrechts-Universität zu Kiel

nachricht Oxygen loss in the coastal Baltic Sea is “unprecedentedly severe”
05.07.2018 | European Geosciences Union

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Future electronic components to be printed like newspapers

A new manufacturing technique uses a process similar to newspaper printing to form smoother and more flexible metals for making ultrafast electronic devices.

The low-cost process, developed by Purdue University researchers, combines tools already used in industry for manufacturing metals on a large scale, but uses...

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

A smart safe rechargeable zinc ion battery based on sol-gel transition electrolytes

20.07.2018 | Power and Electrical Engineering

Reversing cause and effect is no trouble for quantum computers

20.07.2018 | Information Technology

Princeton-UPenn research team finds physics treasure hidden in a wallpaper pattern

20.07.2018 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>